Boxed Warning Added to Tofacitinib Prescribing Information
The FDA has approved changes to the prescribing information for tofacitinib to include new warnings, including a Boxed Warning, regarding an increased risk of blood clots and death.
All articles by Diana Ernst, RPh
Apremilast Approved for Oral Ulcers Associated With Behçet Disease
The FDA has approved Otezla (apremilast; Celgene) for the treatment of adult patients with oral ulcers associated with Behçet’s disease.
Extended-Release Tofacitinib Monotherapy Effectively Treats Severe RA After MTX Withdrawal
The ORAL Shift study enrolled 694 RA patients who were inadequate responders to methotrexate alone.
Febuxostat Labeling Updated With Boxed Warning After Review of Safety Data
The prescribing information for Uloric (febuxostat; Takeda) is being updated to include a Boxed Warning regarding an increased risk of cardiovascular (CV) death and all-cause mortality in patients treated with the gout drug.
Next post in Gout
